Contact: [email protected]
* Studie on hold
Research Team
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| EZH-1201 | All | >SOC | Moderate hepatic: bili 1.5 to 3xULN; Severe hepatic: bili >=3xULN; PK study tazemetostat |
| BT5528-100 | Urothelial | >SOC | Bicyclic peptide (EphA2 + MMAE) |
| CodeBreak 101 (20190135)* | KRASG12C | >1L | Sotorasib + FOLFIRI + Panitumumab; CRC |
| 20210023 | MTAP loss (Sq. NSCLC) | >SOC | MTAP Expression central; oral AMG193 (PRMT5 inhibitor) |
| Fortitude-301 (20210104)* | NSCLC only adenoca. | Several | FGFR2b+; Bemarituzumab (AMG552) |
| WP43295* | BRAFV600 | >SOC | Solid tumors with BRAF (mono or combo); RO7276389 |
| ORIGAMI-1* | CRC (wt) | 2L | Anti-EGFR+MET; chemo + amivantamab |
| DO2.22.01 | MET | >SOC | MET mutation / MET ampl (>10GCN); DO-2 oral |
| BI1456-0001 | All solid | >SOC | BI 1831169 oncolytical virus VSV-GP intratumoral |
| GO43860 | NSCLC (CPI-naive), GC | >SOC | RO7502175 Anti-CCR8 Ab + Atezolizumab |
| PYX-201-101* | Multiple | >SOC | PYX-201: ADC (anti-EDB+fibronectin+auristatin); NSCLC/HNSCC/Ovar/Breast/PDAC/Sarc/Uro/Thyroid |
| IMC-F106C-101 | HLA+PRAME | >SOC | IMC-F106C: Anti-CD3+Tcell receptor; mono or combo; Cut. Melan/Uterine/Endom/NSCLC/Ovarian |
| Bayer 21820* | GC/GEJ/Melanoma | >SOC | BAY3375968: Anti-CCR8 Ab +/- pembro |
| SC201 (VICTORIA-01) | All solid, without liver m+ | >SOC | SOT201: Fusion protein, PD-1 targeted IL-15 agonist |
| Bayer 21948 | Melanoma, NSCLC, RCC, GC, GEJ | >SOC | BAY 2965501: DGKz inhibitor |
| U31402-277 (HERTHENA-PanTumor01) | Several | Several | U3-1402: Patritumab Deruxtecan (HER3-DXd), IV, Q3W Prostate/Ovarian/Cervical/Bladder/Endometrial/Pancreas |
| BI1438-0007 (DAREON-7) | NEC | 1L | BI764532 + etoposide + platinum in DLL3+ |
| IL15 TransDC | Pancreas | >1L | IL15 TransDC vaccin (6 vaccinations, concomitant anti-cancer therapy possible 7D after V2) |
| CDR404-001 | HLA+MAGE-A4 | >SOC | CDR404: MHC specific T-cell engager; NSCLC/HNSCC/Uro/TNBC/Syn. sarcoma/Sq. cervical/Liposarcoma/Endom./GC/GEJ/EC/Ovarian |
| 20230223 | MTAP loss (PDAC) | 1L | MTAP expression central; Oral AMG193 (PRMT5 inhibitor) + gemcitabine/nab-paclitaxel or FOLFIRINOX |
| JK06.1.01 | Several | >SOC | JK06: ADC (anti-5T4 + MMAE); Bladder/Breast/Cervical/STS/Prostate/RCC/Endom./GC/GEJ/HNSCC/NSCLC/Ovarian |
| TAK676-1002 (iintune-1) | HNSCC | 1L | TAK676: STING agonist; In combination with pembrolizumab and chemotherapy |
| BI1479-0012 (Beamion BCGC-1) | mBC, mGEAC HER2 amplification | >1L | BI1810631: HER2 inhibitor; In combination with T-DXd or T-DM1 (cohort-dependent) |
| BI1479-0009 (Beamion PANTUMOR-1) | Several | >SOC | Monotherapy BI1810631: HER2 inhibitor; HER2 amplification (i.e., 6 copies): biliary tract/uterine/cervical/non-Sq. NSCLC or HER2 mutated: urothelial/breast/GEC |